Isoptin

Verapamil, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage hypertension, angina pectoris, and specific cardiac arrhythmias in adult patients requiring cardiovascular therapy.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its distribution network ensures timely delivery and compliance with local import regulations.

Isoptin (verapamil) is used to treat cardiovascular conditions that involve excessive calcium influx into cardiac and vascular smooth muscle. Hypertension: reduces systemic vascular resistance and cardiac output, helping patients achieve guideline‑recommended blood pressure targets and decreasing the risk of cardiovascular complications. Angina pectoris: lowers heart rate and myocardial contractility while dilating coronary arteries, which together reduce oxygen demand and improve blood flow to relieve exertional chest pain. Cardiac arrhythmias (e.g., supraventricular tachycardia): prolongs atrioventricular nodal refractory period and slows conduction, facilitating conversion to sinus rhythm and preventing rapid ventricular rates that can compromise hemodynamics.

Verapamil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools and occasional abdominal discomfort. - Dizziness or light‑headedness: transient drop in blood pressure causing a sensation of faintness. - Headache: mild to moderate intensity headache that may improve with continued therapy. - Peripheral edema: swelling of ankles or feet due to vasodilation and fluid retention. - Nausea: upset stomach with possible vomiting, usually mild and self‑limiting.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall that can lead to syncope or shock. - Bradycardia: abnormally slow heart rate that may require medical evaluation and possible dose adjustment. - Heart block: impairment of electrical conduction in the heart, potentially causing syncope or need for pacemaker.

When prescribing verapamil, clinicians should consider several precautionary measures to ensure patient safety. Cardiovascular assessment: check for heart block, severe left‑ventricular dysfunction, or low blood pressure before starting. Concomitant beta‑blockers: avoid unless closely monitored because of additive bradycardia risk. Liver impairment: consider dose reduction and monitor liver enzymes in hepatic disease. Elderly patients: initiate therapy at a lower dose and watch for heightened hypotensive response. Drug interactions: assess for CYP3A4 inhibitors or inducers that could change verapamil levels. Store at ambient temperature: keep tablets below 25 °C in original packaging, protected from moisture.

Verapamil interacts with several medicines; understanding the interaction potential helps avoid adverse outcomes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise verapamil plasma levels, increasing toxicity risk. - Digoxin: concurrent use can elevate digoxin concentrations, leading to digoxin toxicity. - Beta‑blockers (e.g., propranolol): combined effect may cause